Extracorporeal Therapies Sub Registry
Extracorporeal therapies (ECT), such as hemodialysis, are critically important tools in the treatment of poisoned patients. In the last two decades, major changes have occurred in the nature, utilization, and availability of different types of ECT – including, among others, changes in hemodialysis filter technology, the rise of utilization of continuous renal replacement therapies, the sharp increase in the usage of extracorporeal membrane oxygenation in adults within the last five years, and a number of newly emerging therapies such as the extracorporeal liver assist device. Existing literature regarding the use of extracorporeal therapies to treat poisoning likely does not take all of these changes into account. The rate at which therapies are modified or introduced may make it difficult to adequately study use in poisoned patients through single-institution avenues, especially given that the use of ECT for all but a few poisonings is relatively rare. In addition, very detailed case information about the use of dialysis for poisoning in a sizeable number of patients is nearly impossible to assemble from existing sources.
The purpose of the ToxIC Extracorporeal Therapies Registry is to gather detailed information about patients treated with any form of extracorporeal therapy which can facilitate extracorporeal removal of poisons including: hemodialysis; peritoneal dialysis; continuous renal replacement therapy; hemoperfusion; any form of apheresis; albumin dialysis; and novel forms of extracorporeal therapy. The main goals of this registry are to describe current utilization of ECT for poisoning from an epidemiological standpoint, and assist in determining how effective different forms of ECT are for the treatment of various poisonings.
Authorship Guidelines for the ECT Sub Registry
All medical toxicologists who contribute cases to the registry may be listed as members of the ToxIC Extracorporeal Therapies Study Group, which will be credited in all publications stemming from the subregistry. Individuals with significant administrative involvement in the development and maintenance of the registry will also be considered part of the group and are eligible for individual authorship.
Lead authorship will belong to the investigators initiating and producing the study from the registry data. Individually listed authors will include 1-2 investigators from the site contributing the greatest number of cases to the registry, as well as a single investigator from the next three sites contributing the next greatest number of cases to the registry.
Each listed author is required to: 1) make a substantial contribution to conception and design, acquisition of data, or analysis and interpretation of data; 2) assist in drafting the paper or revising it critically for important intellectual content; and 3) give final approval of the version to be published.
Principal Investigator Contact Information
Joshua D. King, MD
Assistant Professor, Division of Nephrology and Division of Medical Toxicology
University of Virginia School of Medicine
and review the ECT Sub Registry form.